A study in the Journal of Gastroenterology and Hepatology claims patients with chronic hepatitis C prefer dual oral therapy to triple therapy involving pegylated interferon, the Doctors Lounge reports.
Here’s what you should know.
1. The Postgraduate Institute of Medical Education and Research’s Sandeep Satsangi with his colleagues analyzed data for 158 patients that were treated in dual therapy with sofosbuvir and ribavirin for 24 weeks to those in triple therapy adding pegylated interferon for 12 weeks.
2. Of the 158 patients, 65.18 percent of them received the dual treatment, while 34.81 percent received triple therapy.
3. Patients rejected the triple therapy because of "resentment to receive injections, inaccessibility to a facility, a fear of injection and its side effects or financial constraints."
4. All the patients in the triple group, and 98 percent of the patients in the dual group completed the treatment, and all who reached the end sustained a virological response at 12 weeks.
Despite three patients with anemia, there were no side effects.
5. The authors concluded that the oral treatment was preferred to the triple therapy.
More news related to gastroenterology/endoscopy:
Vitamin A metabolite may suppress colorectal cancer: 5 study insights
Migraines associated with GI disorders: 5 study insights
Hannibal Regional Medical Group adds Dr. Ashraf Almashhrawi: 5 things to know